Hyperlipidemia and the rheumatic diseases

Current Opinion in Rheumatology

Volumn 8, Issue 5, 1996, Pages 455-458

  Ilowite, Norman T ^a  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; DIET THERAPY; DYSLIPOPROTEINEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029835902     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199609000-00011     Document Type: Article

References (24)

1. Meller J, Conde CA, Deppisch LM, Donoso E, Dack S: Myocardial Infarction due to coronary atherosclerosis in three young adults with systemic lupus erythematosus. Am J Cardiol 1975, 35:309-314.
2. Spiera H, Rothenberg RR: Myocardial infarction in four young patients with systemic lupus erythematosus. J Rheumatol 1983, 10:464-466.
3. Homcy CJ, Liberthson RR, Fallon JT, Gross S, Miller LM: Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases. Am J Cardiol 1982, 49:478-484.
4. Haider VS, Roberts WC: Coronary arterial disease in systemic lupus erythematosus: qualification of degrees of narrowing in 22 necropsy patients (21 women) aged 16-37 years. Am J Med 1981, 70:775-781.
5. Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975, 58:243-264.
6. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR: Dyslipoproteinemia in systemic lupus erythematosus: effect of cortlcosteroids. Am J Med 1987, 83:503-508.
7. Ilowite N, Samuel P, Ginzler E, Jacobson MS: Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988, 31:859-863.
8. Ilowite N, Samuel P, Beseler L, Jacobson MS: Dyslipoproteinemia in juvenile rheumatoid arthritis. J Pediatr 1989, 114:823-826.
9. Borba EF, Santos RD, Bonfa E, Vinagre CG, Pileggi FJ, Cossermelli W, Maranhao RC: Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994, 21:220-223.
10. Kawai S, Mizushima Y, Kaburaki J: Increased serum lipoprotein(a) levels in systemic lupus erythematosus with myocardial and cerebral infarctions. J Rheumatol 1995, 22:1210-1211. Levels of Lp(a) are elevated in SLE patients with a history of myocardial or cerebral infarction compared with those without such a history.
11. Jacobson MS, Tractman H, Feldman J, Samuel P, Ilowite NT: Dyslipoproteinemia in murine systemic lupus erythematosus. Atherosclerosis 1989, 79:205-211.
12. Zuckerman SH, Bryan-Poole N: Estrogen-induced alterations in Ilpoprotein metabolism In autoimmune MRL//pr mice. Arterioscler Thromb Vasc Biol 1995, 15:1556-1562. Estrogen treatment of MRL//pr mice resulted in increased cholesterol content of LDL particles.
13. Yamaguchi Y, Kitagawa S, Imaizumi N, Kunitomo M, Fujiwara M: Effects of cholesterol loading on autoimmune MRL-lpr//pr mice: susceptibility to hypercholesterolemla and aortic cholesterol deposition. Jpn J Pharmacol 1993, 61:291-298.
14. Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS: Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 1995, 22:1347-1351. National Cholesterol Education Program step I diets lowered triglyceride levels in pediatric SLE patients significantly. Fish oil supplementation further lowered triglyceride levels significantly. However, approximately half of the patients continued to have DL. Pharmacologic therapy may be necessary to control DL in pediatric SLE patients to reduce atherosclerosis risk.
15. Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE: Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995, 22:450-454. Cholesterol, LDL-C, HDL-C, and triglyceride levels did not significantly improve on NCEP step I diets for 6 months, but cholesterol levels did improve on step II dietary modification.
16. Wallace DJ, Metzger AL, Stechler VJ, Turnbull BA, Kern PA: Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1987, 89:322-326.
17. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH: The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993, 20:661-665.
18. Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259.
19. Vaarala O, Alfthan G, Jauhiainene M, Leirisalo-Repo M, Aho K, Palosuo T: Crossreactlon between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993, 341:923-925.
20. Mizutani H, Kurata Y, Kosugi S, Shiraga M, Kashiwagi H, Tomiyama Y, Kanakura Y, Good RA, Matsuzawa Y: Monoclonal anticardiolipin autoantibodies established from the (New Zealand white × BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995, 38:1382-1388. Serum and monoclonal antibodies derived from these mice (a murine antiphospholipid antibody syndrome model) cross-react with ox-LDL, an atherogenic lipoprotein.
21. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, Isenberg DA: Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992, 51:152-155.
22. Lahita RG, Rivkin E, Cavanaugh I, Romano P: Low levels of total cholesterol, high density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993, 36:1566-1574.
23. Merrill JT, Rivkin E, Shen C, Lahita RG: Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. Arthritis Rheum 1995, 38:1655-1659. Mouse apolipoprotein A-I gene products were cloned and found to have structural homology with and to be immunologically related to human apolipoprotein A and may be an antigenic target in SLE patients.
24. Magilavy DB, Zhan R, Black DD: Modulation of murine hepatic lipase activity by exogenous and endogenous Kupffer-cell activation. Biochem J 1993, 292:256.